Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Fasoracetam
Also known as: NFC-1, NS-105, LAM-105
Fasoracetam is a newer racetam compound notable for its unique ability to upregulate GABA-B receptors. Originally developed by Nippon Shinyaku for dementia, it was later acquired by Aevi Technologies and entered Phase II trials for ADHD in adolescents with specific glutamatergic gene variants.
Risk Level
Low RiskDifficulty
Advanced| CAS Number | 110958-19-5 |
| Molecular Formula | C10H16N2O3 |
| Class | Other |
| Category | Nootropics |
Mechanism of Action
Fasoracetam upregulates GABA-B receptors, which is unique among racetams and may reverse tolerance to GABAergic substances like phenibut and baclofen. It also stimulates metabotropic glutamate receptors (mGluR), enhances high-affinity choline uptake similarly to pramiracetam, and increases acetylcholine release in the cerebral cortex. Its GABA-B upregulation mechanism is particularly relevant for individuals with GABA system dysregulation.
Dosing Research
Research doses: 100-800 mg/day (clinical trials used 100-400 mg twice daily for ADHD). Community doses typically 20-100 mg sublingually. Sublingual administration preferred due to uncertain oral bioavailability. Half-life approximately 4-6.5 hours. Limited dosing data — approach conservatively.
Side Effects & Risks
Limited human safety data but generally appears well-tolerated in clinical trials. Headache, fatigue, GI discomfort reported. Theoretical concern: could cause GABA system disruption if combined with GABAergic substances. No known serious adverse effects in short-term studies. Long-term safety profile not established.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.